(12 intermediate revisions by 4 users not shown) | |||
Line 11: | Line 11: | ||
(Written by Florian Albrecht) | (Written by Florian Albrecht) | ||
Shoutout to the 2016 U of C wiki */ | Shoutout to the 2016 U of C wiki */ | ||
− | + | t | |
/* Start general reset ================================================== */ | /* Start general reset ================================================== */ | ||
html body {font-size: inherit;font-family: inherit;background-color: transparent;color: inherit;padding: 0;} | html body {font-size: inherit;font-family: inherit;background-color: transparent;color: inherit;padding: 0;} | ||
Line 81: | Line 81: | ||
} | } | ||
#slide0{ | #slide0{ | ||
− | background-image: url("https://static.igem.org/mediawiki/2016/ | + | background-image: url("https://static.igem.org/mediawiki/2016/5/54/T--Lethbridge_HS--labresultspic--.jpeg"); |
background-size:cover; | background-size:cover; | ||
background-position: center center; | background-position: center center; | ||
Line 804: | Line 804: | ||
<span class="icon-bar"></span> | <span class="icon-bar"></span> | ||
</button> | </button> | ||
− | <a class="navbar-brand" href=" | + | <a class="navbar-brand" href="https://2016.igem.org/Team:Lethbridge_HS" style="color:#CC141C; margin-top:20%;"><img src="https://static.igem.org/mediawiki/2016/5/50/T—lethbridgehs--whitelogo_and.png" width="70"></a> |
</div> | </div> | ||
Line 817: | Line 817: | ||
<a href="https://2016.igem.org/Team:Lethbridge_HS/Description">DESCRIPTION</a> | <a href="https://2016.igem.org/Team:Lethbridge_HS/Description">DESCRIPTION</a> | ||
<a href="https://2016.igem.org/Team:Lethbridge_HS/Design">DESIGN</a> | <a href="https://2016.igem.org/Team:Lethbridge_HS/Design">DESIGN</a> | ||
+ | <a href="https://2016.igem.org/Team:Lethbridge_HS/Prototype">PROTOTYPE</a> | ||
+ | <a href="https://2016.igem.org/Team:Lethbridge_HS/Proof">PROOF OF CONCEPT</a> | ||
<a href="https://2016.igem.org/Team:Lethbridge_HS/Experiments">EXPERIMENTS</a> | <a href="https://2016.igem.org/Team:Lethbridge_HS/Experiments">EXPERIMENTS</a> | ||
<a href="https://2016.igem.org/Team:Lethbridge_HS/Results">RESULTS</a> | <a href="https://2016.igem.org/Team:Lethbridge_HS/Results">RESULTS</a> | ||
+ | <a href="https://2016.igem.org/Team:Lethbridge_HS/Achievements">ACHIEVEMENTS</a> | ||
</li> | </li> | ||
</ul> | </ul> | ||
Line 829: | Line 832: | ||
<a href="https://2016.igem.org/Team:Lethbridge_HS/Basic_Part">BASIC PARTS</a> | <a href="https://2016.igem.org/Team:Lethbridge_HS/Basic_Part">BASIC PARTS</a> | ||
<a href="https://2016.igem.org/Team:Lethbridge_HS/Composite_Part">COMPOSITE PARTS</a> | <a href="https://2016.igem.org/Team:Lethbridge_HS/Composite_Part">COMPOSITE PARTS</a> | ||
− | |||
</li> | </li> | ||
</ul> | </ul> | ||
Line 841: | Line 843: | ||
<li> | <li> | ||
<a href="https://2016.igem.org/Team:Lethbridge_HS/Human_Practices">HUMAN PRACTICES</a> | <a href="https://2016.igem.org/Team:Lethbridge_HS/Human_Practices">HUMAN PRACTICES</a> | ||
+ | <a href="https://2016.igem.org/Team:Lethbridge_HS/HP/Silver">SILVER</a> | ||
+ | <a href="https://2016.igem.org/Team:Lethbridge_HS/HP/Gold">GOLD</a> | ||
<a href="https://2016.igem.org/Team:Lethbridge_HS/Integrated_Practices">INTEGRATED HUMAN PRACTICES</a> | <a href="https://2016.igem.org/Team:Lethbridge_HS/Integrated_Practices">INTEGRATED HUMAN PRACTICES</a> | ||
<a href="https://2016.igem.org/Team:Lethbridge_HS/Engagement">ENGAGEMENT</a> | <a href="https://2016.igem.org/Team:Lethbridge_HS/Engagement">ENGAGEMENT</a> | ||
Line 850: | Line 854: | ||
− | + | ||
+ | |||
+ | <li class= "dropdown"> | ||
+ | <a href="#" class="dropdown-toggle" data-toggle = "dropdown">NOTEBOOK<b class="caret"></b></a> | ||
+ | <ul class="dropdown-menu"> | ||
+ | <li> | ||
+ | <a href="https://2016.igem.org/Team:Lethbridge_HS/Notebook">NOTEBOOK</a> | ||
+ | <a href="https://2016.igem.org/Team:Lethbridge_HS/Methods">METHODS</a> | ||
+ | |||
+ | </li> | ||
+ | </ul> | ||
+ | </li> | ||
+ | |||
+ | |||
+ | |||
<li><a href="https://2016.igem.org/Team:Lethbridge_HS/Safety" style="" class="menuitem" style="margin:0; padding:0; ">SAFETY</a></li> | <li><a href="https://2016.igem.org/Team:Lethbridge_HS/Safety" style="" class="menuitem" style="margin:0; padding:0; ">SAFETY</a></li> | ||
Line 866: | Line 884: | ||
</li> | </li> | ||
− | <li><a href=" | + | <li><a href="https://igem.org/Main_Page" style="" class="menuitem" style="margin:0; padding:0 ">IGEM</a></li> |
</ul> | </ul> | ||
</div> | </div> | ||
Line 874: | Line 892: | ||
<div class="jumbotron slide" id="slide0" style=""> | <div class="jumbotron slide" id="slide0" style=""> | ||
<div class="container-fluid" style="margin-left:10%;"> | <div class="container-fluid" style="margin-left:10%;"> | ||
− | <h1 id="firsttitle" style=""> <b> | + | <h1 id="firsttitle" style=""> <b>RESULTS</b></h1> |
<!--<div style="position:relative;"> | <!--<div style="position:relative;"> | ||
<video width="100%" autoplay muted loop style="float:left; position:absolute; z-index:5;"> | <video width="100%" autoplay muted loop style="float:left; position:absolute; z-index:5;"> | ||
Line 887: | Line 905: | ||
<div class="container-fluid" style="margin-left:10%; margin-right:10%;"> | <div class="container-fluid" style="margin-left:10%; margin-right:10%;"> | ||
<div class="row"> | <div class="row"> | ||
− | + | ||
− | + | <div class="col-md-12"> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | <div class="col-md- | + | |
− | + | ||
<a name="first"></a> | <a name="first"></a> | ||
− | < | + | |
− | < | + | <img src="https://static.igem.org/mediawiki/2016/a/a4/T%E2%80%94lethbridgehs--graph_and.jpeg" width="100%"> |
− | < | + | |
− | < | + | |
− | < | + | <table class="table table-striped table-bordered"> |
− | < | + | |
+ | <caption>Clot Times</caption> | ||
+ | <thead> | ||
+ | <tr> | ||
+ | <th>Treatment</th> | ||
+ | <th>Time</th> | ||
+ | <th>Half Clot Time</th> | ||
+ | </tr> | ||
+ | </thead> | ||
+ | <tbody> | ||
+ | <tr> | ||
+ | <td>70 mg heparin blood, 1 mL viper construct</td> | ||
+ | <td>0</td> | ||
+ | <td>31</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td> | ||
+ | 70 mg heparin blood, 1 mL PNRa | ||
+ | </td> | ||
+ | <td>1</td> | ||
+ | <td>33</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td> | ||
+ | 70 mg heparin blood, 2 mL PNRA | ||
+ | </td> | ||
+ | <td>2</td> | ||
+ | <td>41</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td> | ||
+ | 70 mg heparin blood, 2 mL viper construct | ||
+ | </td> | ||
+ | <td>3</td> | ||
+ | <td>54</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td> | ||
+ | 70 mg heparin blood, 0 cells | ||
+ | </td> | ||
+ | <td>4</td> | ||
+ | <td>44</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td> | ||
+ | 71 mg heparin blood, 2 mL PNRA | ||
+ | </td> | ||
+ | <td>5</td> | ||
+ | <td>57</td> | ||
+ | </tr> | ||
+ | |||
+ | <tr> | ||
+ | <td> | ||
+ | |||
+ | 71 mg heparin blood, 1 mL viper construct | ||
+ | |||
+ | </td> | ||
+ | <td>6</td> | ||
+ | <td>67</td> | ||
+ | </tr> | ||
+ | |||
+ | <tr> | ||
+ | <td> | ||
+ | |||
+ | 71 mg heparin blood, no cells | ||
+ | |||
+ | </td> | ||
+ | <td>7</td> | ||
+ | <td>48</td> | ||
+ | </tr> | ||
+ | |||
+ | </tbody> | ||
+ | </table> | ||
+ | |||
+ | <img src="https://static.igem.org/mediawiki/2016/5/55/T%E2%80%94lethbridgehs--bloodpics_and.jpeg" width="60%"> | ||
+ | <p><br>The half clot time of different treatments on the blood was tested and calculated. Specifically, the clotting time of our blood was tested with 70mg of heparin as well as 71mg of heparin in different trials, in addition to either 1mL or 2mL of PNRA or 1mL or 2mL of our construct in order to determine the effects of our construct on the blood clotting pathway. A positive control was also set by having blood with heparin with no cells, to ensure the blood did not spontaneously clot on its own. In general, we were able to show that our construct caused the blood to clot. Although these are preliminary tests, we plan to optimize our construct further in the future in order to determine the resulting flow rates after our construct is applied to ensure that it does not impact the rate of blood flow throughout the rest of the patient’s body.</br> | ||
+ | </p> | ||
</div> | </div> | ||
Latest revision as of 03:55, 20 October 2016
Treatment | Time | Half Clot Time |
---|---|---|
70 mg heparin blood, 1 mL viper construct | 0 | 31 |
70 mg heparin blood, 1 mL PNRa | 1 | 33 |
70 mg heparin blood, 2 mL PNRA | 2 | 41 |
70 mg heparin blood, 2 mL viper construct | 3 | 54 |
70 mg heparin blood, 0 cells | 4 | 44 |
71 mg heparin blood, 2 mL PNRA | 5 | 57 |
71 mg heparin blood, 1 mL viper construct | 6 | 67 |
71 mg heparin blood, no cells | 7 | 48 |
The half clot time of different treatments on the blood was tested and calculated. Specifically, the clotting time of our blood was tested with 70mg of heparin as well as 71mg of heparin in different trials, in addition to either 1mL or 2mL of PNRA or 1mL or 2mL of our construct in order to determine the effects of our construct on the blood clotting pathway. A positive control was also set by having blood with heparin with no cells, to ensure the blood did not spontaneously clot on its own. In general, we were able to show that our construct caused the blood to clot. Although these are preliminary tests, we plan to optimize our construct further in the future in order to determine the resulting flow rates after our construct is applied to ensure that it does not impact the rate of blood flow throughout the rest of the patient’s body.